Journals / Türkderm-Deri Hastalıkları ve Frengi Arşivi / 2015 / Cilt: 49 - Sayı: 2

Toxic epidermal necrolysis due to concomitant use of valproic asid and lamotrigine

Lamotrijin ve valproik asidin birlikte kullanımı sonucunda gelişen toksik epidermal nekroliz olgusu

Pages
169–172
Publication Date
2022-11-05
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

Early determination of complications and suitable management can increase the odds for survival. (Turkderm 2015; 49: 169-72)

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Toxic epidermal necrolysis (TEN) is a rare but life-threatening acute mucacutaneous hypersensitivity reaction, usually related to medications.
📊
Key Findings & Data:A 36-year-old male was admitted to the emergency department with the complaints of high fever, burning sensation at eyes, oral and genital mucous erosions, generalized rush and weakness.
💡
Conclusion & Impact:Early determination of complications and suitable management can increase the odds for survival. (Turkderm 2015; 49: 169-72)
🔬Design:Research Article
📍Scope:2015 Verileri
⚙️Variables:Domain Parameters

Abstract

Toxic epidermal necrolysis (TEN) is a rare but life-threatening acute mucacutaneous hypersensitivity reaction, usually related to medications. Concomitant use of lamotrigine and valproic acid can cause this serious reaction. A 36-year-old male was admitted to the emergency department with the complaints of high fever, burning sensation at eyes, oral and genital mucous erosions, generalized rush and weakness. He had been taking valproic asid, olanzapine, and sertraline for bipolar affective disorder. Lamotrigine 25 mg/day treatment was added to his treatment protocol 15 days before the rush and lamotgine dose was increased 50 mg/day 10 days later. The patient was diagnosed with TEN caused by concomitant use of valproic acid and lamotrigine. The patient was followed up and treated at the burn unit with intravenous immunoglobulin, corticosteroid and antibiotics. Concomitant use of valproic acid and lamotrigine increases the frequency of adverse reaction. TEN may cause serious complications and death. Patients with TEN should be followed by a multi-disciplinary team. Early determination of complications and suitable management can increase the odds for survival. (Turkderm 2015; 49: 169-72)

Özet

Toksik epidermal nekroliz (TEN) nadir görülen, genellikle ilaç kullanımına bağlı gelişen, ani başlangıçlı, yaşamı tehdit eden, deri ve mukozaları etkileyen aşırı duyarlılık reaksiyonudur. Lamotrijin ve valproik asidin birlikte kullanılması bu ciddi reaksiyona neden olabilir. Otuz altı yaşındaki erkek hasta acil servis kliniğine yüksek ateş, gözlerde yanma hissi, oral ve genital mukozada erezyonlar, yaygın döküntü ve halsizlik şikayeti ile başvurdu. Hasta duygu durum bozukluğu nedeni ile valproik asid, olanzapin, ve sertralin kullanmakta idi. Döküntüleri başlamadan 15 gün önce tedavi protokolüne 25 mg/gün lamotrijin ilave edildiği ve lamotrijin dozunun 10 gün sonra 50 mg/gün dozuna arttırıldığı öğrenildi. Hasta TEN tanısı ile yanık ünitesine yatırılarak intravenöz immunoglobulin, kortikosteroid ve antibiyotik uygulanarak tedavi ve takibi yapıldı. Valproik asid ve lamotrijinin birlikte kullanılması yan etki sıklığını arttırmaktadır. Toksik epidermal nekroliz ciddi komplikasyonlar ve ölüme neden olabilir. Hastalar tıbbi bir ekip tarafından takip edilmelidir. Komplikasyonların erkenden belirlenmesi ve uygun şekilde tedavi edilmeleri hastaların yaşam şansını arttıracaktır. (Türk­derm 2015; 49: 169-72)

🔖

Cite This Article

ÖZCAN, H. (2022). Toxic epidermal necrolysis due to concomitant use of valproic asid and lamotrigine. Türkderm-Deri Hastalıkları ve Frengi Arşivi, Cilt: 49 - Sayı: 2, 169–172. https://ajindex.com/articles/621772

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (15)

  1. Schwartz RA, McDonough PH, Lee BW: Toxic epidermal necrolysis: Part I. Introduction, history, classification, clinical features, systemic manifestations, etiology, and immunopathogenesis. J Am Acad Dermatol 2013;69:173.e1- 13; quiz 185-6
  2. Tseng HW, Chang CH: Toxic epidermal necrolysis due to lamotrigine monotherapy for bipolar disorder. Tzu Chi Medical Journal 2009;21:165-8
  3. Bhushan M, Brooke R, Hewitt-Symonds M, Craven NM, August PJ: Prolonged toxic epidermal necrolysis due to Lamotrigine. Clin Exp Dermatol 2000;25:349-51
  4. Serdar ZA, Yaşar Ş, Döner N, Doruk T, Engin DÖ, Güneş P: Lamotrijin kullanımı ile ilişkili antikonvülzan hipersensitivite sendromu: Olgu Sunumu. Türk Aile Hek Der 2010;14:192-195
  5. Mansur AT, Pekcan Yaşar S, Göktay F: Anticonvulsant hypersensitivity syndrome: clinical and laboratory features. Int J Dermatol 2008;47:1184-9
  6. Varghese SP, Haith LR, Patton ML, Guilday RE, Ackerman BH: Lamotrigine- induced toxic epidermal necrolysis in three patients treated for bipolar disorder. Pharmacotherapy 2006;26:699-704
  7. Oflaz S, Kalkan HS, Gokce E, Karşidag C, Gurel MS: Stevens Johnson syndrome - toxic epidermal necrolysis induced by combination of lamotrigine and valproic acid: A case report. Bull Clin Psychopharmacol 2011;21:150-3
  8. Levi N, Bastuji-Garin S, Mockenhaupt M, et al: Medications as risk factors of Steven-Johnson Syndrome and Toxic Epidermal Necrolysis in children: A pooled analysis. Pediatrics 2009;123:297-304
  9. Fogh K, Mai J: Toxic epidermal necrolysis after treatment with lamotrigine (Lamictal). Seizure 1997;6:63-5
  10. Uğuz A, Berber Z, Haspolat Ş, ve ark: Lamotrijine bağlı Stevens-Johnson sendromu-toksik epidermal nekroliz: Bir olgu sunumu. Turkiye Klinikleri J Pediatr 2005;14:36-9
  11. Sladden M, Mortimer N, Chave T. Toxic epidermal caused by lamotrigine. Aust Fam Physician 2004;33:829-30
  12. Hirsch LJ, Weintraub DB, Buchsbaum R, Spencer HT, Straka T, Hager M: Predictors of lamotrigine-associated rash. Epilepsia 2006;47:318-22
  13. Page RL 2nd, O'Neil MG, Yarbrough DR 3rd, Conradi S: Fatal toxic epidermal necrolysis related to lamotrigine administration. Pharmacotherapy 1998;18:392-8
  14. Bastuji-Garin S1, Fouchard N, Bertocchi M, Roujeau JC, Revuz J, Wolkenstein P: SCORTEN: a severity-of-illness score for toxic epidermal necrolysis. J Invest Dermatol 2000;115:149-53
  15. Guegan S, Bastuji-Garin S, Poszepczynska-Guigne E, Roujeau JC, Revuz J: Performance of the SCORTEN during the first five days of hospita